Format

Send to

Choose Destination
Clin Transl Oncol. 2017 Jan;19(1):58-66. doi: 10.1007/s12094-016-1503-3. Epub 2016 Mar 30.

Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.

Author information

1
Department of General Thoracic and Esophageal Surgery, Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
2
Department of Surgery, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
3
Department of Gastroenterologic and General Surgery, Helsinki University Hospital, Haartmaninkatu 4, PO Box 340, 00290, Helsinki, Finland.
4
Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland.
5
Department of Surgery, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. pauli.puolakkainen@hus.fi.
6
Department of Gastroenterologic and General Surgery, Helsinki University Hospital, Haartmaninkatu 4, PO Box 340, 00290, Helsinki, Finland. pauli.puolakkainen@hus.fi.

Abstract

BACKGROUND:

Clinically useful marker molecules for the progression of gastroesophageal reflux disease and Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) are lacking. Many adenocarcinomas and inflammatory conditions exhibit increased expression of ADAMs, 'a disintegrin and metalloproteinases'.

METHODS:

We assessed the expression of five ADAMs (9, 10, 12, 17, 19) in three esophageal cell lines (Het-1A, OE19, OE33) by RT-PCR and Western blotting, and in human samples of normal esophagus, esophagitis, BE, Barrett's dysplasia, and EAC by RT-PCR, and in selected samples by immunohistochemistry.

RESULTS:

EAC patients showed increased mRNA expression of ADAMs 9, 12, 17 and 19, as compared to controls. At immunohistochemistry, ADAM9 and ADAM10 proteins were increased in EAC. Patient samples also showed increased mRNA expression of ADAM12 in esophagitis, of ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett's dysplasia, as compared to controls. Two EAC cell lines showed increased ADAM9 mRNA.

CONCLUSIONS:

ADAM9 expression is increased in EAC. Its predecessors show increased ADAM9 mRNA expression. The importance of the alterations in ADAM expression for the development of EAC, and their use as marker molecules, warrant further studies.

KEYWORDS:

ADAM molecules; Barrett’s esophagus; Esophageal adenocarcinoma; Gastroesophageal reflux disease

PMID:
27026568
DOI:
10.1007/s12094-016-1503-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center